Stockreport

Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate

Vaxart, Inc.  (VXRT) 
Last vaxart, inc. earnings: 3/19 04:01 pm Check Earnings Report
PDF Study met 5 of 6 primary endpoints Vaccine was safe and well tolerated with no vaccine-related serious adverse events (SAEs) Vaccination led to a statistically signifi [Read more]